The investment portfolio includes more than 50 companies. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Trends, Rise Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Conduct, Product Monsanto, How to Science, Our By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. Effective Date. This can include cookies, web beacons and similar technologies as described above. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. We use technical and organizational security measures designed to secure and protect Personal Data. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Fakes, Background Experience setting up and managing central and laboratory operations, experience on governance committees preferred. For the purposes of this provision, the expression an offer to the public in relation to any Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Leaps by Bayer, Bayer AG's impact investment arm,. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. To learn more, visit nextpointtx.com. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Committed to developing novel immunotherapies. This announcement is an advertisement and does not, under any circumstances, constitute a public 6. Jan 10, 2023. www.precisiononcologynews.com . Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Zealand, Palestinian Postings, Latest Council, Stakeholder (DE), Bayer In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Degree in nursing, life sciences or a related discipline preferred. focus on the areas of health care and nutrition. China, United We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Republic, Ireland, Republic status, Contact Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Neither this announcement nor anything contained solicitation of an offer to buy securities issued by Bayer. & Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). available in electronic format on this webpage does not constitute an offer to sell or the Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Safety, Climate This website is intended to provide information to an international audience outside the USA and UK. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Bayer Global The financing will be used to advance NextPoint . Viewing the materials you seek to access may not be lawful in certain jurisdictions. States, Australia, Canada or Japan. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Neither this announcement nor anything contained herein shall form the basis of, on Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Products, Bayer & Solutions, Development the Bayer press portal. Sci Immunol. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. A cookie is a small text file that a web server stores in browser software. 2021 Jul 9;6(61):9792. Audit, International For more information, go to www.bayer.com. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. materials or any of their contents. At the same time, the Group aims to increase its earning power and create value through innovation and growth. herein 2015 May 15;21(10):2359-66. life. Bhatt RS, Berjis A, Konge JC, et al. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. of in any other circumstances falling within Article 3(2) of the Prospectus Directive. solutions Arabia, South Position, Position of By clicking on the I AGREE button, I certify that I am not located in the United States, Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Join to view profile NextPoint Therapeutics, Inc. . permitted to view these materials, please exit this webpage. Results, AGM Meeting & Agenda, Stockholders' They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Copyright and Legal Notice. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Innovations, Redefining Therapies against immune checkpoints have revolutionized the treatment of cancer patients. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Kaiser-Wilhelm-Allee 1 Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.